The German pharmaceutical company STADA will purchase the pharmaceutical business of the leading Ukrainian company Biopharma. The STADA's annual revenue exceeds € 2.3 billion (as of December 2018) and employs over 10,400 people worldwide.
“For Ukraine, the coming of such an investor is a landmark event. This means new jobs and paid taxes instead of just simple importing and selling goods here. And it is also access to the advanced technologies, research and solutions, as well as to export markets,” said Prime Minister Oleksiy Honcharuk.
The PM added that STADA's decision to enter the Ukrainian market proves that the confidence of international business in Ukraine is growing. In turn, attracting foreign investment is one of the main drivers of economic growth, which is the key to the well-being of every Ukrainian citizen.
The acquisition of assets is expected to complete by the end of 2019.